[usPropHeader] Error loading user control: The file '/CMSWebParts/WK.HLRP/LNC/LNCProductHeader.ascx' does not exist.


  1. Belavic, Jennifer PharmD

Article Content

Do you know what they contain? Match the brand names in Section I with the generic ingredients in Section II.



_____ 1. Humira (Abbott)


_____ 2. Enbrel (Amgen/Pfizer)


_____ 3. Kineret (Amgen)


_____ 4. Remicade (Centocor Ortho Biotech)



a. etanercept 50 mg/mL, 25 mg multiple-use vial

This tumor necrosis factor (TNF) blocker is indicated for patients with moderately to severely active rheumatoid arthritis (RA). Common adverse reactions include infections and injection-site reactions. The drug should be discontinued if a serious infection or sepsis develops.


b. infliximab 100 mg/20 mL

Given with methotrexate, this TNF blocker slows the progression of joint damage in patients with moderately to severely active RA. Patients may experience acute infusion reaction with fever, chills, pruritus, and rash within 1 to 2 hours of administration. If a serious infection develops, therapy should be stopped.


c. adalimumab 20 mg/0.4 mL, 40 mg/0.8 mL

This drug can be used alone or with methotrexate or other disease-modifying antirheumatic drugs (DMARDs). The most common adverse reactions include injection-site reactions, infections, headache, and rash. Monitor patients for severe allergic reactions, including anaphylaxis.


d. anakinra 100 mg/0.67 mL

A recombinant interleukin-1 (IL-1) receptor antagonist, this drug binds to IL-1 type I receptors on target cells to slow the progression of structural damage. The drug can be combined with DMARDs other than TNF-blocking agents. The most common adverse reaction is local injection-site reactions.

Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.